Literature DB >> 26081218

The low levels of circulating hepatocyte growth factor in nephrolithiasis cases: independent from gene polymorphism.

Nurinnisa Ozturk1, Hulya Aksoy2, Yilmaz Aksoy3, Abdulkadir Yildirim2, Fatih Akcay2, Vefa Yanmaz4.   

Abstract

Environmental and genetic factors are important in development of nephrolithiasis. In a recent study, it has been demonstrated that hepatocyte growth factor (HGF) has an anti-apoptotic effect and thus can reduce the adhesion of calcium oxalate monohydrate crystals to renal epithelial cells. The aim of this study was to evaluate the HGF serum levels and its two gene polymorphisms and possible association of the two in patients with nephrolithiasis. One hundred and five patients with nephrolithiasis and 70 healthy volunteers with similar demographic features were included in this study. Serum HGF levels were measured, and HGF intron 13 C>A (in 102 stone patients and 68 healthy subjects) and intron 14 T>C (in 99 stone patients and 56 healthy subjects) polymorphisms were determined using real-time polymerase chain reaction with TaqMan allelic discrimination method. There were no statistically significant differences in HGF intron 13 C>A and intron 14 T>C polymorphisms between the control and patient groups (X (2) = 1.72 df = 2; p = 0.42, and X (2) = 0.68 df = 2; p = 0.71, respectively). Mean serum HGF concentration was significantly lower in the stone disease patients than in the control subjects (1.05 ± 0.63 pg/mL and 1.35 ± 0.58 ng/mL respectively, p = 0.0001). When allele distribution frequency between stone patients and healthy subjects was compared, there were no significant differences in intron 13 and intron 14 allele distributions between two groups (p = 0.43 and p = 0.44, respectively). It may be concluded from the findings that decrease in HGF levels may play a role in renal stone formation, independent from gene polymorphisms.

Entities:  

Keywords:  Gene polymorphism; Hepatocyte growth factor; Nephrolithiasis; Serum hepatocyte growth factor level

Mesh:

Substances:

Year:  2015        PMID: 26081218     DOI: 10.1007/s00240-015-0793-1

Source DB:  PubMed          Journal:  Urolithiasis        ISSN: 2194-7228            Impact factor:   3.436


  33 in total

Review 1.  Hepatocyte growth factor: molecular biomarker and player in cardioprotection and cardiovascular regeneration.

Authors:  R Madonna; C Cevik; M Nasser; R De Caterina
Journal:  Thromb Haemost       Date:  2012-02-08       Impact factor: 5.249

2.  In vivo hepatocyte growth factor gene transfer reduces myocardial ischemia-reperfusion injury through its multiple actions.

Authors:  Xue-Hai Chen; Shinya Minatoguchi; Kenichiro Kosai; Kentaro Yuge; Tomoyuki Takahashi; Masazumi Arai; Ningyuan Wang; Yu Misao; Chuanjiang Lu; Hirohito Onogi; Hiroyuki Kobayashi; Shinji Yasuda; Masayasu Ezaki; Hiroaki Ushikoshi; Genzou Takemura; Takako Fujiwara; Hisayoshi Fujiwara
Journal:  J Card Fail       Date:  2007-12       Impact factor: 5.712

3.  Crystal-cell interaction and apoptosis in oxalate-associated injury of renal epithelial cells.

Authors:  S R Khan; K J Byer; S Thamilselvan; R L Hackett; W T McCormack; N A Benson; K L Vaughn; G W Erdos
Journal:  J Am Soc Nephrol       Date:  1999-11       Impact factor: 10.121

Review 4.  Epidemiology and medical management of stone disease.

Authors:  H-G Tiselius
Journal:  BJU Int       Date:  2003-05       Impact factor: 5.588

Review 5.  Genetic causes of hypercalciuric nephrolithiasis.

Authors:  Michael J Stechman; Nellie Y Loh; Rajesh V Thakker
Journal:  Pediatr Nephrol       Date:  2008-04-30       Impact factor: 3.714

6.  Fetuin-A gene polymorphism in patients with calcium oxalate stone disease.

Authors:  Hulya Aksoy; Yilmaz Aksoy; Nurinnisa Ozturk; Hasan Riza Aydin; A Kadir Yildirim; Fatih Akçay
Journal:  Urology       Date:  2009-11-22       Impact factor: 2.649

7.  A vascular modulator, hepatocyte growth factor, is associated with systolic pressure.

Authors:  Y Nakamura; R Morishita; S Nakamura; M Aoki; A Moriguchi; K Matsumoto; T Nakamura; J Higaki; T Ogihara
Journal:  Hypertension       Date:  1996-09       Impact factor: 10.190

8.  A polymorphism of matrix Gla protein gene is associated with kidney stones.

Authors:  Bing Gao; Takahiro Yasui; Yasunori Itoh; Keiichi Tozawa; Yutaro Hayashi; Kenjiro Kohri
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

9.  Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction.

Authors:  A Matsumori; Y Furukawa; T Hashimoto; K Ono; T Shioi; M Okada; A Iwasaki; R Nishio; S Sasayama
Journal:  Biochem Biophys Res Commun       Date:  1996-04-16       Impact factor: 3.575

10.  Hepatocyte growth factor and myopia: genetic association analyses in a Caucasian population.

Authors:  Tammy Yanovitch; Yi-Ju Li; Ravikanth Metlapally; Diana Abbott; Khanh-Nhat Tran Viet; Terri L Young
Journal:  Mol Vis       Date:  2009-05-20       Impact factor: 2.367

View more
  1 in total

1.  Kidney Diseases: The Age of Molecular Markers.

Authors:  Glaucia Luciano da Veiga; Beatriz da Costa Aguiar Alves; Matheus Moreira Perez; Joyce Regina Raimundo; Jéssica Freitas de Araújo Encinas; Neif Murad; Fernando Luiz Affonso Fonseca
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.